43.43
price down icon0.34%   -0.15
after-market Handel nachbörslich: 43.25 -0.18 -0.41%
loading

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

pulisher
05:34 AM

Ultragenyx Pharmaceutical (RARE) Projected to Post Quarterly Earnings on Thursday - MarketBeat

05:34 AM
pulisher
Feb 11, 2025

WCM Investment Management LLC Has $5.73 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by abrdn plc - MarketBeat

Feb 11, 2025
pulisher
Feb 08, 2025

RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study - MSN

Feb 08, 2025
pulisher
Feb 07, 2025

Ultragenyx Pharmaceuticals: Buy Rating Supported by Promising Gene Therapy Trial Results and Regulatory Advancements - TipRanks

Feb 07, 2025
pulisher
Feb 07, 2025

Brokerages Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) PT at $92.43 - MarketBeat

Feb 07, 2025
pulisher
Feb 06, 2025

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update - GlobeNewswire

Feb 06, 2025
pulisher
Feb 06, 2025

Rare Disease Leader Ultragenyx to Reveal Full Year Performance: Key Earnings Date Announced - StockTitan

Feb 06, 2025
pulisher
Feb 06, 2025

UX111 offers cognitive, motor skill gains in Sanfilippo syndrome type A - Sanfilippo News

Feb 06, 2025
pulisher
Feb 06, 2025

Rett Syndrome Market Growth Projections 2024-2034: - openPR

Feb 06, 2025
pulisher
Feb 06, 2025

Adicet's T-Cell Therapy ADI-100 Fast Tracked by FDA for Refractory Systemic Lupus Erythematosus - CGTLive™

Feb 06, 2025
pulisher
Feb 06, 2025

Ultragenyx announces new data on UX111 AV gene therapy - Yahoo Finance

Feb 06, 2025
pulisher
Feb 06, 2025

Ultragenyx updates on UX111 AAV gene therapy - The Pharma Letter

Feb 06, 2025
pulisher
Feb 05, 2025

Ultragenyx links cognitive improvement to biomarker in latest Sanfilippo gene therapy readout - FirstWord Pharma

Feb 05, 2025
pulisher
Feb 05, 2025

Ultragenyx Announces New Data Demonstrating that Treatment - GlobeNewswire

Feb 05, 2025
pulisher
Feb 05, 2025

Ultragenyx Pharmaceutical Presents New Data for UX111 Gene Therapy, Expects FDA Approval Decision in H2 - Marketscreener.com

Feb 05, 2025
pulisher
Feb 05, 2025

Ultragenyx reports positive data on gene therapy for rare disease - MSN

Feb 05, 2025
pulisher
Feb 05, 2025

Ultragenyx reports positive data on gene therapy for rare disease By Investing.com - Investing.com South Africa

Feb 05, 2025
pulisher
Feb 05, 2025

Breakthrough: Ultragenyx's Gene Therapy Reverses Cognitive Decline in Fatal Childhood Disease - StockTitan

Feb 05, 2025
pulisher
Feb 05, 2025

KBC Group NV Buys 58,442 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Feb 05, 2025
pulisher
Jan 30, 2025

Mucopolysaccharidosis Type III Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Takeda Pharma, BioMarin Pharma, Ultragenyx Pharma, Sarepta - Barchart

Jan 30, 2025
pulisher
Jan 29, 2025

Ultragenyx Pharmaceutical: Advancing On Multiple Fronts (NASDAQ:RARE) - Seeking Alpha

Jan 29, 2025
pulisher
Jan 28, 2025

Wilson’s Disease Market Expected to rise, 2034 | Orphalan, AstraZeneca,Vivet Therapeutics,Pfizer,Ultragenyx Pharmaceutical, expected to drive market - Barchart

Jan 28, 2025
pulisher
Jan 28, 2025

Allogene Therapeutics’ ALLO-329 Cleared by FDA for Phase 1 Clinical Trial in Rheumatology Indications - CGTLive™

Jan 28, 2025
pulisher
Jan 28, 2025

Learn to Evaluate (RARE) using the Charts - Stock Traders Daily

Jan 28, 2025
pulisher
Jan 27, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) adds US$374m to market cap in the past 7 days, though investors from three years ago are still down 37% - Simply Wall St

Jan 27, 2025
pulisher
Jan 27, 2025

What is Wedbush’s Estimate for RARE FY2024 Earnings? - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

Wedbush Has Positive Outlook for RARE FY2027 Earnings - Defense World

Jan 26, 2025
pulisher
Jan 24, 2025

Wedbush Equities Analysts Boost Earnings Estimates for RARE - MarketBeat

Jan 24, 2025
pulisher
Jan 23, 2025

Ultragenyx's SWOT analysis: rare disease stock poised for growth - Investing.com India

Jan 23, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Forecasts RARE FY2025 Earnings - Defense World

Jan 23, 2025
pulisher
Jan 23, 2025

FY2024 Earnings Estimate for RARE Issued By Leerink Partnrs - Defense World

Jan 23, 2025
pulisher
Jan 23, 2025

Mucopolysaccharidosis (MPS) Treatment Market Growth in Future - openPR

Jan 23, 2025
pulisher
Jan 22, 2025

Ultragenyx's SWOT analysis: rare disease stock poised for growth By Investing.com - Investing.com Australia

Jan 22, 2025
pulisher
Jan 22, 2025

Breaking Down Ultragenyx Pharmaceutical: 11 Analysts Share Their Views - Benzinga

Jan 22, 2025
pulisher
Jan 22, 2025

Ultragenyx Pharmaceutical's (RARE) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Leerink Partnrs Has Positive Outlook of RARE FY2024 Earnings - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Cantor Fitzgerald Predicts RARE FY2025 Earnings - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Sells 76,160 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World

Jan 22, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Decreases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Jan 22, 2025
pulisher
Jan 18, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jan 18, 2025
pulisher
Jan 18, 2025

FY2024 EPS Estimates for RARE Boosted by Cantor Fitzgerald - Defense World

Jan 18, 2025
pulisher
Jan 17, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 5.7%Should You Sell? - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential - Insider Monkey

Jan 17, 2025
pulisher
Jan 17, 2025

12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey

Jan 17, 2025
$32.34
price up icon 0.28%
$19.57
price up icon 2.57%
$4.63
price up icon 3.58%
$370.74
price up icon 4.93%
biotechnology ONC
$223.31
price up icon 0.94%
$111.89
price down icon 2.28%
Kapitalisierung:     |  Volumen (24h):